natgillin/translations-raw huggingface dataset:
Melphalan Concomitant use with melphalan leads to increased risk of pulmonary toxicity.
Sočasna uporaba z melfalanom povečuje tveganje za zastrupitev pljuč.
Severe (end-stage) renal impairment.
Huda (končna) okvara ledvic.
What Carmustine Obvius is and what it is used for
Kaj je zdravilo Karmustin Obvius in za kaj ga uporabljamo
Posology and laboratory investigations
Odmerjanje in laboratorijske preiskave
After reconstitution Carmustine Obvius is stable for 3 hours, stored in a glass container and protected from light.
Po rekonstituciji je zdravilo Karmustin Obvius stabilno tri ure, shranjeno v steklenem vsebniku in zaščiteno pred svetlobo.
Intravenously administered carmustine is rapidly degraded, with no substance intact detectable after 15 minutes.
Intravensko aplicirani karmustin se hitro razgrajuje in po 15 minutah ni več zaznavne intaktne snovi.
Any sudden wheeziness, difficulty in breathing, swelling of the eyelids, face or lips, rash or itching (especially affecting your whole body), and feeling you are going to faint.
Kakršno koli nenadno piskanje, težave z dihanjem, otekanje vek, obraza ali ustnic, izpuščaj ali srbenje (še posebej, če je prizadeto vse vaše telo) in občutek, da boste omedleli.
Interstitial fibrosis (with lower doses).
Intersticijska fibroza (pri manjših odmerkih).
Concomitant use with digoxin leads to delayed, moderate, suspected, decreased effect of digoxin (due to the decreased digoxin absorption).
Sočasna uporaba z digoksinom povzroči odložen, zmeren, domnevni zmanjšani učinek digoksina (zaradi zmanjšane absorpcije digoksina).
Carmustine must be completely dissolved in ethanol before sterile water for injections is added.
Karmustin je treba pred dodatkom sterilne vode za injekcije popolnoma raztopiti v etanolu.
Carmustine Obvius will always be given to you by a healthcare professional with experience in the use of anticancer medicines.
Zdravilo Karmustin Obvius vam bo vedno dal zdravstveni delavec z izkušnjami z uporabo zdravil proti raku.
In case of a decreased number of circulating platelets, leucocytes or erythrocytes either from previous chemotherapy or other cause the dose should be adjusted, see Table 1, section 4.2.
V primeru zmanjšanega števila trombocitov, levkocitov ali eritrocitov v obtoku zaradi predhodne kemoterapije ali drugega vzroka je treba odmerek prilagoditi; glejte preglednico 1, poglavje 4.2.
Therefore your doctor will monitor blood counts weekly for at least 6 weeks after a dose.
Zdravnik bo zato vsaj šest tednov po odmerku tedensko spremljal število krvnih celic.
Carmustine Obvius contains ethanol (alcohol)
Zdravilo Karmustin Obvius vsebuje etanol (alkohol)
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness:
V razvrstitvah pogostnosti so neželeni učinki navedeni po padajoči resnosti:
There are no limits for the period of application of carmustine therapy.
Za trajanje zdravljenja s karmustinom ni časovnih omejitev.
Carmustine Obvius may cause the following side effects:
Zdravilo Karmustin Obvius lahko povzroči naslednje neželene učinke:
Do not use this medicine after the expiry date which is stated on the label and carton after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki in škatli poleg oznake „UPORABNO DO“.
Nausea and vomiting are severe and begins within 2-4 h of administration and lasts for 4-6 h.
Slabost in bruhanje sta huda in se začneta v dveh do štirih urah po dajanju ter trajata od štiri do šest ur.
if you suffer from suppression of blood cell formation in the bone marrow and the number of your platelets, white blood cells (leucocytes), or red blood cells (erythrocytes) is therefore reduced, either as a result of chemotherapy or other causes.
če trpite zaradi zavrte tvorbe krvnih celic v kostnem mozgu in je zato število trombocitov, belih krvnih celic (levkocitov) ali rdečih krvničk (eritrocitov) zaradi kemoterapije ali drugih razlogov pri vas zmanjšano;
In addition, carmustine is known to carbamoylate lysine residues on proteins causing irreversible inactivation of enzymes including glutathione reductase.
Poleg tega je za karmustin znano, da karbamoilira lizinske ostanke na beljakovinah, s čimer povzroča ireverzibilno inaktivacijo encimov, vključno z glutation reduktazo.
When Carmustine Obvius is used in combination with other myelosuppressive medicinal products or in patients in whom bone marrow reserve is depleted, the doses should be adjusted according to the haematologic profile of the patient as shown below.
Kadar se zdravilo Karmustin Obvius uporablja v kombinaciji z drugimi mielosupresivnimi zdravili ali pri bolnikih, pri katerih je porabljena rezerva kostnega mozga, je treba odmerke prilagoditi glede na hematološki profil bolnika, kot je prikazano spodaj.
Pulmonary toxicity also manifested in the post-marketing phase as pneumonitis and interstitial lung disease.
Zastrupitev pljuč se je pokazala tudi v obdobju trženja, in sicer kot pnevmonitis in intersticijska bolezen pljuč.
What you need to know before you use Carmustine Obvius Do not use Carmustine Obvius:
Kaj morate vedeti, preden boste uporabili zdravilo Karmustin Obvius Ne uporabljajte zdravila Karmustin Obvius:
if you suffer from higher-grade kidney dysfunction.
če imate motnjo delovanja ledvic višje stopnje;
For storage conditions after reconstitution and further dilution of the medicinal product, see section 6.3.
Za pogoje shranjevanja po rekonstituciji in nadaljnjem redčenju zdravila glejte poglavje 6.3.
Carmustine Obvius has no or negligible influence on the ability to drive and use machines.
Zdravilo Karmustin Obvius nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Cytotoxic: Handle with caution.
Citotoksično: Ravnajte previdno.
However, the possibility will have to be taken into consideration, that the alcohol quantity in these pharmaceutical medicines can impair the ability to drive and use machines.
Vendar je treba upoštevati možnost, da lahko količina alkohola v teh farmacevtskih zdravilih vpliva na sposobnost vožnje in upravljanja strojev.
If such symptoms occur, you should contact your doctor immediately (see section
Če se pojavijo tovrstni simptomi, se takoj obrnite na svojega zdravnika
To be taken into account in pregnant or breast-feeding women, children and highrisk groups such as patients with liver disease, or epilepsy.
To je treba upoštevati pri nosečnicah ali doječih materah, otrocih in ogroženih skupinah, kot so bolniki z boleznijo jeter ali epilepsijo.
Leucocytes/mm3
Levkociti/mm3
The dosage will be confirmed with the blood count.
Odmerek je treba potrditi s krvno sliko.
Each ampoule of solvent contains 3 ml ethanol anhydrous (that is equivalent to 2.37 g).
Vsaka ampula z vehiklom vsebuje 3 ml brezvodnega etanola (kar ustreza 2,37 g).
Since the use of Carmustine Obvius can lead to lung damage, an X-ray of the chest region and lung function tests will be conducted before treatment is started (please also see the section “Possible side effects”).
Ker lahko uporaba zdravila Karmustin Obvius povzroči poškodbo pljuč, bodo pred začetkom zdravljenja opravljeni rentgensko slikanje predela prsnega koša in testi pljučne funkcije (prosimo, glejte tudi poglavje Možni neželeni učinki).
The powder is white to almost white powder supplied in a brown glass vial.
Prašek je bel do skoraj bel prašek v viali iz rjavega stekla.
Carmustine Obvius is contraindicated during breastfeeding and up to seven days post-treatment (see section 4.3).
Zdravilo Karmustin Obvius je med dojenjem in do sedem dni po zdravljenju kontraindicirano (glejte poglavje 4.3).
Repeat doses of Carmustine Obvius should not to be given more frequently than every six weeks.
Ponovni odmerki zdravila Karmustin Obvius se ne smejo dajati pogosteje kot na vsakih šest tednov.
It is able to form interstrand crosslinks in DNA, which prevents DNA replication and transcription.
V DNA lahko tvori prečne povezave med verigami, s čimer preprečuje podvajanje in prepisovanje DNA.
What Carmustine Obvius is and what it is used for What you need to know before Carmustine Obvius is given to you How to use Carmustine Obvius
Kaj je zdravilo Karmustin Obvius in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli zdravilo Karmustin Obvius Kako uporabljati zdravilo Karmustin Obvius
Very common Hypotension, due to the alcohol content of the solvent (high-dose therapy).
Zelo pogosti Hipotenzija zaradi vsebnosti alkohola v vehiklu (zdravljenje z velikimi odmerki).
By reconstituting the powder with the solvent provided, a solution has to be prepared by adding additional 27 ml water for injections.
Po rekonstituciji praška s priloženim vehiklom je treba pripraviti raztopino z dodajanjem dodatnih 27 ml vode za injekcije.
Pulmonary toxicity characterised by pulmonary infiltrates and/or fibrosis has been reported to occur with a frequency ranging up to 30%.
Poročali so o pojavljanju zastrupitve pljuč, za katero so značilni pljučni infiltrati in/ali fibroza, z do 30-odstotno pogostnostjo.
Rare (may affect up to 1 in 1,000 people) - Veno-occlusive disease (progressive blockage of the veins) where very small (microscopic) veins in the liver are blocked.
Redki (pojavijo se lahko pri največ 1 od 1 000 bolnikov) - venookluzivna bolezen (napredujoča zapora ven), pri kateri pride do zapore zelo majhnih (mikroskopskih) ven v jetrih.
Carmustine belongs to a group of anticancer medicines known as nitrosourea that act by slowing the growth of cancer cells.
Karmustin spada v skupino zdravil proti raku, imenovanih nitrozosečnine, ki delujejo tako, da upočasnjujejo rast rakavih celic.
Pharmacotherapeutic group: Antineoplastic agents, alkylating agents, nitrosoureas, ATC code: L01AD01
Farmakoterapevtska skupina: Zdravila z delovanjem na novotvorbe; alkilirajoči citostatiki; derivati nitrozosečnine, oznaka ATC: L01AD01
You must not breast-feed while taking this medicine and up to 7 days after treatment.
Med jemanjem tega zdravila in do sedem dni po zdravljenju ne smete dojiti.
Adverse reactions are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials,
Neželeni učinki so na splošno vključeni, če so o njih poročali pri več kot enem odstotku bolnikov v monografiji zdravila ali ključnih preskušanjih in/ali so ugotovili, da so klinično pomembni.
For patients with renal impairment the dose of Carmustine Obvius should be reduced if the glomerular filtration rate is reduced.
Pri bolnikih z okvaro ledvic je treba odmerek zdravila Karmustin Obvius zmanjšati, če se hitrost glomerulne filtracije zmanjša.
The bone marrow toxicity of carmustine is cumulative and therefore the dosage adjustment must be considered on the basis of nadir blood counts from prior doses (see section
Toksičnost karmustina za kostni mozeg je kumulativna, zato je treba razmisliti o prilagoditvi odmerka na podlagi najmanjšega števila krvnih celic po predhodnih odmerkih (glejte poglavje 4.2).
Phenytoin and dexamethasone
Fenitoin in deksametazon
Carmustine and related nitrosoureas are unstable in aqueous solutions and degrade spontaneously to reactive intermediates that are capable of alkylation and carbamoylation.
Karmustin in sorodne nitrozosečnine so v vodni raztopini nestabilni in spontano razpadejo v reaktivne intermediate, ki lahko učinkujejo alkilirajoče in karbamoilirajoče.
Guidelines for the safe disposal of antineoplastic agents must be observed.
Upoštevati je treba smernice za varno odstranjevanje antineoplastičnih zdravil.
Infusion of Carmustine Obvius in less than one hour may produce intense pain and burning at the site of injection (see section 4.2).
Infundiranje zdravila Karmustin Obvius, ki traja manj kot eno uro, lahko povzroči močno bolečino in pekočino na mestu injiciranja (glejte poglavje 4.2.
Carmustine Obvius is a medicine which contains carmustine.
Karmustin Obvius je zdravilo, ki vsebuje karmustin.
Nausea and vomiting - severe
Slabost in bruhanje - hudo
This can result in increased liver enzymes and bilirubin (detected by blood tests); - Alopecia (loss of hair); - Flushing of the skin; - Reactions on the injection site
To lahko povzroči zvišanje ravni jetrnih encimov in bilirubina (izmerjeno s preiskavami krvi); - alopecija (izguba las); - pordelost kože; - reakcije na mestu injiciranja.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without prescription, such as: Phenytoin, used in epilepsy
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo, vključno z zdravili brez recepta, na primer:
Common Alopecia, flushing (due to alcohol content of solvent; increased with administration times <1-2 h), injection site reaction.
Alopecija, zardevanje (zaradi vsebnosti alkohola v vehiklu; poveča se s časom dajanja < 1-2 uri), reakcija na mestu injiciranja.
As an alkylating agent, it can alkylate reactive sites on nucleoproteins, thus interfering with DNA and RNA synthesis and DNA repair.
Kot alkilirajoča učinkovina lahko alkilira reaktivna mesta na nukleoproteinih, s čimer ovira sintezo DNA in RNA ter popravljanje DNA.
If you use more Carmustine Obvius than you should
Če ste uporabili večji odmerek zdravila Karmustin Obvius, kot bi smeli
Other medicines and Carmustine Obvius
Druga zdravila in zdravilo Karmustin Obvius
The amount of alcohol in this medicinal product may alter the effects of other medicines, and may impair your ability to drive or use machines.
Količina alkohola v tem zdravilu lahko spremeni učinke drugih zdravil in vpliva na sposobnost vožnje ali upravljanja strojev.
Common Acute leukaemia, bone marrow dysplasia - following long-term use.
Akutna levkemija, displazija kostnega mozga - po dolgotrajni uporabi.
The lyophilisate can appear as a fine powder, however handling can cause it to appear as a more heavy and lumpy lyophilisate than as a powdery lyophilisate due to the mechanical instability of the freeze drying cake.
Liofilizat je lahko videti kot droben prašek, vendar ob ravnanju z njim zaradi mehanske nestabilnosti bolj daje vtis težjega in grudičastega kot praškastega liofilizata.
This medicinal product contains 0.57 vol% ethanol (alcohol), i.e. up to 7.62 g per dose, equivalent to 11.2 ml beer or 4.65 ml wine per dose.
To zdravilo vsebuje 0,57 vol% etanola (alkohola), tj. do 7,62 g na odmerek, kar je enakovredno 11,2 ml piva ali 4,65 ml vina na odmerek.
The solvent is a colourless clear liquid supplied in a clear glass ampule.
Vehikel je brezbarvna bistra tekočina v prozorni stekleni ampuli.
If Carmustine Obvius is used during pregnancy, or if the patient becomes pregnant while taking (receiving) Carmustine Obvius, the patient should be apprised of the potential hazard to the foetus.
Če se zdravilo Karmustin Obvius uporablja med nosečnostjo ali če bolnica med jemanjem (prejemanjem) zdravila Karmustin Obvius zanosi, je treba bolnico seznaniti z možnimi tveganji za plod.
Further, the ready-to-use solutions needs to be protected from light (e.g. using alu-foil wrapped around the container of the Ready-to-Use solution) and preferably kept at temperatures below 20-22°C as carmustine degrades faster at higher temperatures.
Poleg tega je treba za dajanje pripravljeno raztopino zaščititi pred svetlobo (npr. z uporabo aluminijaste folije, zavite okrog vsebnika z raztopino, pripravljeno za uporabo) in po možnosti shraniti pri temperaturah pod 2022 °C, saj zdravilo Karmustin Obvius pri višjih temperaturah hitreje razpade.
The incidence of adverse reactions is probably doserelated; cumulative doses of 1200-1500 mg/m2 have been associated with an increased likelihood of pulmonary fibrosis.
Incidenca neželenih učinkov je verjetno odvisna od odmerka; kumulativni odmerki od 1 200 do 1 500 mg/m2 so bili povezani z večjo verjetnostjo pljučne fibroze.
Carmustine, at clinically relevant dose levels, was carcinogenic in rats and mice.
Karmustin je bil v odmerkih klinično pomembne ravni karcinogen pri podganah in miših.
May cause birth defects.
Lahko povzroči prirojene okvare.
Concomitant use with cimetidine leads to delayed, major, suspected, increased carmustine toxic effect (due to the inhibition of carmustine metabolism).
Sočasna uporaba s cimetidinom povzroči odložen, velik, domnevni in povečani toksični učinek karmustina (zaradi zaviranja presnove karmustina).
Common Hepatotoxicity, reversible, delayed up to 60 days after administration (high-dose therapy and dose-limiting), manifested by: - bilirubin, reversible increase - alkaline phosphatase, reversible increase - SGOT, reversible increase.
Hepatotoksičnost, reverzibilna, pojavi se do 60 dni po dajanju (zdravljenje z velikimi odmerki in odmerek omejujoča), pokaže se z: - reverzibilnim povečanjem bilirubina; - reverzibilnim povečanjem alkalne fosfataze;
Solvent Clear type I glass ampoule (5 ml).
Vehikel Prozorna steklena ampula razreda I (5 ml).
The reconstituted and diluted solution (i.e. ready-to-use solution) must be given intravenously and should be administered by intravenous drip over a one- to two-hour period and administration should be finalised within 3 hours from reconstitution/dilution of the medicinal product.
Rekonstituirano in razredčeno raztopino (tj. za uporabo pripravljena raztopino) je treba dati intravensko, z eno do dve uri trajajočo intravensko kapalno infuzijo, dajanje pa je treba končati v treh urah od rekonstitucije/redčenja zdravila.
Pneumonitis is seen for doses >450 mg/m2 and interstitial lung disease is seen with prolonged therapy and cumulative dose > 1,400 mg/m2.
Pnevmonitis se pojavi pri odmerkih > 450 mg/m2, intersticijska bolezen pljuč pa se pojavi pri dolgotrajnem zdravljenju in kumulativnem odmerku > 1 400 mg/m2 Emetogeni potencial
The 530 ml diluted solution (i.e. the ready-to-use solution) should be mixed for at least 10 seconds before administration.
530 ml razredčene raztopine (tj. za uporabo pripravljeno raztopino) pred dajanjem vsaj 10 sekund mešajte.
Contents of the pack and other information What Carmustine Obvius contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Karmustin Obvius
Before treatment, your liver, lung and kidney function will be tested and observed regularly during treatment.
Pred zdravljenjem bo pregledano delovanje vaših jeter, pljuč in ledvic, med zdravljenjem pa bo to redno spremljano.
Patients showing a baseline value of <70% of expected forced vital capacity or carbon monoxide diffusion capacity in these tests are at particular risk.
Bolniki, ki imajo pri teh testih izhodiščno vrednost pričakovane forsirane vitalne kapacitete ali difuzijske kapacitete za ogljikov monoksid manjšo od 70 odstotkov, so še posebej ogroženi.
The myelosuppression is dose and cumulative dose related, and often biphasic.
Mielosupresija je odvisna od odmerka in kumulativnega odmerka ter je pogosto dvofazna.
The alkylating intermediates are believed to be responsible for the antitumor effect of carmustine.
Alkilirajoči intermediati naj bi bili vzrok za protitumorski učinek karmustina.
Percentage of prior dose to be given
Delež predhodnega odmerka
Myelosuppression is very common and begins 7-14 days of administration with recovery 4256 days of administration.
Mielosupresija je zelo pogosta in se začne od 7 do 14 dni po dajanju ter izzveni od 42 do 56 dni po dajanju.
Pulmonary toxicity, interstitial fibrosis (with prolonged therapy and cumulative dose)
Zelo pogosti Zastrupitev pljuč, intersticijska fibroza (pri dolgotrajnem zdravljenju in kumulativnem odmerku).
The major side effect of this medicine is delayed bone marrow suppression, which may show as tiredness, bleeding from the skin and mucous membranes as well as infections and fever due to changes in the blood.
Glavni neželeni učinek tega zdravila je zapoznela supresija kostnega mozga, ki se lahko zaradi sprememb v krvi kaže kot utrujenost, krvavitev iz kože in sluznic, okužbe in vročina.
Patients with a baseline below 70% of the predicted forced vital capacity (FVC) or carbon monoxide diffusing capacity (DLCO) are particularly at risk.
Posebej ogroženi so bolniki z izhodiščem pod 70 odstotkov napovedane forsirane vitalne kapacitete ali difuzijske kapacitete za ogljikov monoksid.
Carmustine Obvius must be administered only by specialists experienced in the field of chemotherapy and under appropriate medical supervision
4.2 Odmerjanje in način uporabe Zdravilo Karmustin Obvius smejo dajati samo specialisti z izkušnjami s področja kemoterapije in pod ustreznim zdravniškim nadzorom Odmerjanje
Use of carmustine in children and adolescents < 18 years is contraindicated, see section 4.3.
Uporaba karmustina je kontraindicirana pri otrocih in mladostnikih, mlajših od 18 let, glejte poglavje 4.3.
Carmustine Obvius should not be used in children and adolescents due to high risk of pulmonary toxicity.
Pediatrična populacija Zdravilo Karmustin Obvius se zaradi velikega tveganja za zastrupitev pljuč ne sme uporabljati pri otrocih in mladostnikih.
Keep the vial and ampoule in the outer carton in order to protect from light.
Vialo in ampulo shranjujte v zunanji škatli za zagotovitev zaščite pred svetlobo.
- Brain tumours (glioblastoma, Brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases
- možganskih tumorjih (glioblastomih, gliomih možganskega debla, meduloblastomih, astrocitomih in ependimomih), metastazah v možganih
Carmustine should not be administered to patients who are pregnant.
Karmustin se ne sme dajati nosečim bolnicam.
Long-term follow-up observation of 17 patients who survived brain tumours in childhood showed that 8 of them succumbed to pulmonary fibrosis.
Dolgotrajno spremljanje 17 bolnikov, ki so v otroštvu preživeli možganski tumor, je pokazalo,
The duration of infusion should not be less than one hour, otherwise it leads to burning and pain in the injected area.
Infuzija ne sme trajati manj kot eno uro, sicer lahko v injiciranem predelu povzroči pekoč občutek in bolečino.
Carmustine is a cell-cycle phase nonspecific antineoplastic agent of the nitrosourea type, which exerts tumor cytotoxicity via multiple mechanisms.
Karmustin je za fazo celičnega cikla nespecifična antineoplastična učinkovina nitrozosečninske vrste, ki deluje na tumorje citotoksično na več načinov.
Bone marrow toxicity is a common and severe toxic adverse reaction of carmustine.
Toksičnost kostnega mozga je pogost in hud toksičen neželeni učinek karmustina.
At the recommended dosage, courses of Carmustine Obvius would not be given more frequently than every 6 weeks.
Pri priporočenem odmerku se cikli zdravila Karmustin Obvius ne smejo dajati pogosteje kot na vsakih šest tednov.
Carmustine Obvius with alcohol
Zdravilo Karmustin Obvius z alkoholom
Emetogenic potential The emetogenic potential is high at doses >250 mg/m2 and high to moderate in doses
Emetogeni potencial je velik pri odmerkih > 250 mg/m2 in velik do srednji pri odmerkih
How to use Carmustine Obvius
Kako uporabljati zdravilo Karmustin Obvius
Hepatic and renal function should also be checked prior to treatment and regularly monitored during therapy (see section 4.8).
Pred zdravljenjem je treba preveriti tudi delovanje jeter in ledvic ter njihovo delovanje med zdravljenjem redno spremljati (glejte poglavje 4.8).
Ataxia, dizziness, headache.
Ataksija, omotica, glavobol.
1 ampoule of 3 ml solvent
1 ampula s 3 ml vehikla
Veno-occlusive disease (high-dose therapy).
Venookluzivna bolezen (zdravljenje z velikimi odmerki).
Ocular toxicities, transient conjunctival flushing and blurred vision due to retinal haemorrhages.
Očesna toksičnost, prehodna pordelost veznic in zamegljen vid zaradi mrežničnih krvavitev.
Method of administration Carmustine Obvius is for intravenous use after reconstitution and further dilution.
Zdravilo Karmustin Obvius je namenjeno intravenski uporabi po rekonstituciji in nadaljnjem redčenju.
Infusion of Carmustine Obvius over shorter periods of time may produce intense pain and burning at the site of injection.
Hitrejša infuzija zdravila Karmustin Obvius lahko povzroči močno bolečino in pekočino na mestu injiciranja.
Carmustine Obvius must not be used in children and adolescents aged <18 years.
Zdravilo Karmustin Obvius se ne sme uporabljati pri otrocih in mladostnikih, mlajših od 18 let.